

# Mark Basik

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3656670/publications.pdf>

Version: 2024-02-01

49  
papers

1,760  
citations

304743

22  
h-index

289244

40  
g-index

49  
all docs

49  
docs citations

49  
times ranked

3720  
citing authors

#	ARTICLE	IF	CITATIONS
1	PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. <i>Cell Metabolism</i> , 2015, 22, 577-589.	16.2	430
2	The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression. <i>Cell Reports</i> , 2018, 23, 1476-1490.	6.4	127
3	Biopsies: next-generation biospecimens for tailoring therapy. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 437-450.	27.6	110
4	Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108). <i>Journal of Clinical Oncology</i> , 2022, 40, 978-987.	1.6	86
5	A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA2-LBA2.	1.6	85
6	A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer. <i>Cell Reports</i> , 2017, 21, 1140-1149.	6.4	70
7	Detecting post-translational modification signatures as potential biomarkers in clinical mass spectrometry. <i>Expert Review of Proteomics</i> , 2018, 15, 515-535.	3.0	69
8	Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program. <i>Nature Communications</i> , 2018, 9, 2547.	12.8	63
9	A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability. <i>Molecular Cancer Research</i> , 2019, 17, 2492-2507.	3.4	63
10	Minireview: The Link Between ER $\pm$ Corepressors and Histone Deacetylases in Tamoxifen Resistance in Breast Cancer. <i>Molecular Endocrinology</i> , 2016, 30, 965-976.	3.7	48
11	An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy. <i>Nature Communications</i> , 2019, 10, 2139.	12.8	46
12	Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer. <i>Scientific Reports</i> , 2020, 10, 14704.	3.3	41
13	The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers. <i>Cancer Research</i> , 2015, 75, 4351-4363.	0.9	40
14	Testing devices or experimental systems? Cancer clinical trials take the genomic turn. <i>Social Science and Medicine</i> , 2014, 111, 74-83.	3.8	33
15	The crosstalk between breast carcinoma-associated fibroblasts and cancer cells promotes RhoA-dependent invasion <i>via</i> IGF-1 and PAI-1. <i>Oncotarget</i> , 2018, 9, 10375-10387.	1.8	33
16	SPEN, a new player in primary cilia formation and cell migration in breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 104.	5.0	32
17	MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma <i>In Situ</i> . <i>Cancer Research</i> , 2019, 79, 1646-1657.	0.9	31
18	Immuno-Matrix-Assisted Laser Desorption/Ionization Assays for Quantifying AKT1 and AKT2 in Breast and Colorectal Cancer Cell Lines and Tumors. <i>Analytical Chemistry</i> , 2017, 89, 10592-10600.	6.5	30

#	ARTICLE	IF	CITATIONS
19	Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 4337-4345.	1.5	29
20	Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors. <i>Communications Biology</i> , 2020, 3, 310.	4.4	28
21	Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 91-99.	2.5	26
22	Metastatic Breast Carcinoma-Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression. <i>Clinical Cancer Research</i> , 2019, 25, 7229-7242.	7.0	26
23	STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. <i>Nature Communications</i> , 2021, 12, 3299.	12.8	24
24	Breast cancer mammospheres secrete Adrenomedullin to induce lipolysis and browning of adjacent adipocytes. <i>BMC Cancer</i> , 2020, 20, 784.	2.6	21
25	The MNK1/2-eIF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast Cancer. <i>Cancer Research</i> , 2021, 81, 3876-3889.	0.9	21
26	Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits. <i>Scientific Reports</i> , 2017, 7, 10574.	3.3	20
27	A functional in vitro model of heterotypic interactions reveals a role for interferon-positive carcinoma associated fibroblasts in breast cancer. <i>BMC Cancer</i> , 2015, 15, 130.	2.6	16
28	Identification of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-sensitive and Hormone-resistant Prostate Cancer Cells. <i>Scientific Reports</i> , 2019, 9, 8838.	3.3	15
29	Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naïve advanced breast cancer (MINT).. <i>Journal of Clinical Oncology</i> , 2013, 31, 531-531.	1.6	13
30	Using Two Peptide Isotopologues as Internal Standards for the Streamlined Quantification of Low-Abundance Proteins by Immuno-MRM and Immuno-MALDI. <i>Analytical Chemistry</i> , 2020, 92, 12407-12414.	6.5	11
31	RSF1 and Not Cyclin D1 Gene Amplification May Predict Lack of Benefit from Adjuvant Tamoxifen in High-Risk Pre-Menopausal Women in the MA.12 Randomized Clinical Trial. <i>PLoS ONE</i> , 2013, 8, e81740.	2.5	10
32	NRG Oncology BR005: Phase II trial assessing accuracy of tumor bed biopsies (Bx) in predicting pathologic response in patients (Pts) with clinical/radiological complete response (CR) after neoadjuvant chemotherapy (NCT) in order to explore the feasibility of breast-conserving treatment (BCT) without surgery.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS604-TPS604.	1.6	10
33	HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin. <i>Oncogene</i> , 2022, 41, 1701-1717.	5.9	8
34	Early, On-Treatment Levels and Dynamic Changes of Genomic Instability in Circulating Tumor DNA Predict Response to Treatment and Outcome in Metastatic Breast Cancer Patients. <i>Cancers</i> , 2021, 13, 1331.	3.7	7
35	Precise Quantitation of PTEN by Immuno-MRM: A Tool To Resolve the Breast Cancer Biomarker Controversy. <i>Analytical Chemistry</i> , 2021, 93, 10816-10824.	6.5	7
36	Sentinel node biopsy following neoadjuvant chemotherapy in biopsy proven node positive breast cancer: The SN FNAC study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1018-1018.	1.6	7

#	ARTICLE	IF	CITATIONS
37	A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue Specimens. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4443.	4.1	7
38	Surgical and Oncologic Outcomes of Nipple-Sparing Mastectomy for a Cohort of Breast Cancer Patients, Including Cases with High-Risk Features. <i>Clinical Breast Cancer</i> , 2020, 20, 353-358.	2.4	5
39	Systematic Optimization of the iMALDI Workflow for the Robust and Straightforward Quantification of Signaling Proteins in Cancer Cells. <i>Proteomics - Clinical Applications</i> , 2020, 14, 2000034.	1.6	5
40	Making personalized medicine a reality: the challenges of a modern translational research biopsy-driven program in an academic setting: the Segal Cancer Center experience. <i>Journal of Medicine and the Person</i> , 2011, 9, 104-111.	0.1	3
41	A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110 $\alpha$ in cell lines and tumor tissues. <i>Analyst</i> , 2021, 146, 6566-6575.	3.5	1
42	Q-CROC-03: A prospective biopsy driven clinical trial to study the mechanisms of resistance to chemotherapy in triple-negative breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS1139-TPS1139.	1.6	1
43	Sentinel node biopsy after neoadjuvant therapy: Relevance of sentinel node micrometastases, isolated tumor cells, and value of immunohistochemistry.. <i>Journal of Clinical Oncology</i> , 2013, 31, 52-52.	1.6	1
44	Healthcare policy by other means: Cancer clinical research as "oncopolitics". <i>Social Science and Medicine</i> , 2022, 292, 114576.	3.8	1
45	Clinicopathologic features of breast cancers diagnosed in females treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort.. <i>Journal of Clinical Oncology</i> , 2021, 39, 567-567.	1.6	0
46	Biopsy-driven study to identify biomarkers of drug resistance in patients with triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 87-87.	1.6	0
47	Breast cancer in women aged 80 years and older: Clinical characteristics and treatment patterns according to biologic subtype.. <i>Journal of Clinical Oncology</i> , 2020, 38, e12594-e12594.	1.6	0
48	A novel immune cell signature predicts pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer patients in the Q-CROC3 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, e12614-e12614.	1.6	0
49	Abstract 4011: Prognostic value of transcriptomic analysis in residual post neo-adjuvant triple negative breast cancer tumors. <i>Cancer Research</i> , 2022, 82, 4011-4011.	0.9	0